Fisher Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26M	Buy	2,733,253 +265,686	+11%	+$2.06M	0.01%	302
2025 Q4	$19.2M	Sell	2,467,567 -165,129	-6%	-$1.19M	0.01%	327
2025 Q3	$20M	Sell	2,632,696 -149,793	-5%	-$1.25M	0.01%	322
2025 Q2	$24.9M	Sell	2,782,489 -269,648	-9%	-$2.51M	0.01%	291
2025 Q1	$22.9M	Sell	3,052,137 -130,480	-4%	-$1.05M	0.01%	309
2024 Q4	$23.9M	Sell	3,182,617 -155,445	-5%	-$1.18M	0.01%	326
2024 Q3	$25.4M	Buy	3,338,062 +481,359	+17%	+$3.66M	0.01%	311
2024 Q2	$17.7M	Sell	2,856,703 -27,916	-1%	-$154K	0.01%	353
2024 Q1	$14.7M	Buy	2,884,619 +50	+0%	+$281	0.01%	370
2023 Q4	$17.3M	Sell	2,884,569 -300,630	-9%	-$1.74M	0.01%	346
2023 Q3	$22.6M	Sell	3,185,199 -1,139,354	-26%	-$8.19M	0.01%	335
2023 Q2	$30.4M	Buy	4,324,553 +31,157	+0.7%	+$250K	0.02%	318
2023 Q1	$35.8M	Sell	4,293,396 -137,718	-3%	-$1.33M	0.02%	288
2022 Q4	$50.9M	Sell	4,431,114 -732,731	-14%	-$9.14M	0.03%	240
2022 Q3	$65.1M	Sell	5,163,845 -52,984	-1%	-$682K	0.05%	213
2022 Q2	$55.2M	Buy	5,216,829 +1,230,006	+31%	+$12.7M	0.04%	213
2022 Q1	$64.8M	Sell	3,986,823 -110,229	-3%	-$1.77M	0.04%	215
2021 Q4	$56.7M	Buy	4,097,052 +1,091,430	+36%	+$14.4M	0.03%	233
2021 Q3	$43.2M	Buy	3,005,622 +994,391	+49%	+$15.7M	0.03%	247
2021 Q2	$31.8M	Buy	+2,011,231	New	+$27.3M	0.02%	276